Conjugation is the heart of Antibody-Drug Conjugate (ADC) technology. Where biology meets chemistry. At Aurigene, we offer state-of-the-art conjugation services that ensure precise, stable, and reproducible attachment of payloads to antibodies. Our deep understanding of bioconjugation science, coupled with advanced analytics, allows us to optimize every step, from site selection to linker-payload attachment. Enabling the creation of ADCs with optimal Drug-to-Antibody Ratios (DAR), stability, and therapeutic activity. Whether your goal is preclinical proof-of-concept or gram scale batches, we tailor conjugation strategies to your molecule’s biology, mechanism of action, and intended indication.
Thiol-Maleimide Conjugation
- Standard approach using reduced interchain cysteines
- Controlled DAR (typically 2, 4, or 8)
- Efficient and scalable
Ideal for fast turnaround and widely accepted in early-phase ADC development
Lysine Conjugation
- Non-specific conjugation to surface-exposed lysines
- Produces heterogeneous ADCs
Suitable for early-stage screening and rapid evaluation of new payloads or linkers
Enzymatic Conjugation
- Site-specific conjugation via transglutaminase, sortase, or glycoengineering
- High positional control and consistency
Best for developing next-gen, highly homogeneous ADCs
Branched and Dual Payload Conjugation
- Technologies to enable two different payloads on the same antibody
- Balanced DAR per payload
Designed to overcome tumor heterogeneity or resistance mechanisms
Site-Specific Technologies (Engineered Cysteines)
- Controlled site insertion for cleaner ADCs
Ensures uniform DAR and improved pharmacokinetics
Why choose Aurigene?
At Aurigene, conjugation isn’t just a chemical reaction, it’s a scientifically guided process. We bring over a decade of experience in designing and optimizing conjugation strategies across diverse payloads, linkers, and antibody formats, including bispecifics and Fab fragments. Our conjugation team works hand-in-hand with our analytical, purification, and in vitro biology teams to ensure each ADC meets stringent quality, reproducibility, and performance benchmarks.
We provide:
Expert design of DAR optimization and conjugation strategy
Multiple conjugation formats tailored to indication and payload class
Capability to support cleavable and non-cleavable linkers
Advanced purification to isolate mono-, di-, or specific DAR species
Fully integrated analytics including LC-MS, HIC, SEC, UV-Vis, and endotoxin testing
Seamless transition to in vitro assays, stability studies, and in vivo efficacy models
Whether you are screening novel linker-payloads or developing a clinical candidate, Aurigene ensures your conjugation step is robust, reproducible, and ready for scale-up.
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Connect with our scientific experts for your drug discovery, development, and manufacturing needs
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
Resources
FEBRUARY 25, 2025
Transforming Drug Discovery with Aurigene.AI
In the early 2000s, developing Sovaldi, a hepatitis C treatment, took over a decade and nearly $2 billion. Similarly, Zolgensma, a gene therapy for spinal muscular atrophy, required 15 years due to its complexity. However, the advent of artificial intelligence (AI) has revolutionized drug discovery. For example, in 2022, Pfizer's PAXLOVID, an oral COVID...
Read More
Advancement in personalized medicine and how the CRDMO industry is part of the solution
Personalized medicine is transforming the healthcare landscape by customizing treatment plans to individual patients’ unique genetic, clinical and environmental characteristics. These are effective and less invasive treatments for a wide range of conditions. Contract Research, Development and Manufacturing Organizations (CRDMOs) play an important role...
Read More
Cell Line Development
We enable development of stable and high yielding recombinant Mammalian and Microbial lines. ...
Read More
Familiarization, process optimization, and cGMP manufacturing and supply of 30.0 kg of a Bioactive Nucleotide (NAD Booster)
Background: A US-based biopharmaceutical company approached Aurigene Pharmaceutical Services for the familiarization, process development, and cGMP manufacturing and supply of 30.0 kg Nucleotide product (NAD booster) for phase-appropriate studies. The synthesis of the desired product involves three linear stages, which starts with reaction of a pentose...
Read More
Identification of Degradants of Thermal and Oxidation Stress Studies of Empagliflozin and Linagliptin Tablets by HPLC-PDA and LC-MS Instrumental Techniques
2022
Objective of the manuscript is to identify the degradants observed in the thermal and oxidation degradation sample of Empagliflozin and Linagliptin tablets by using LC-MS and HPLC-PDA instrumental techniques. Thermal and oxidation degradation samples were injected in HPLC-PDA and LC-MS instruments. Mass of the degradants were detected by LC-MS technique, ...
Read More-
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2005
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More -
Wang-OSO3H catalyzed green synthesis of bioactive isoindolo[2,1- a ]quinazoline-5,11–dione derivatives: An unexpected observation
2005
The sulphonic acid-functionalized Wang resin (Wang-OSO3H) was explored as a polymeric and recov- erable acidic catalyst for the synthesis of isoindolo[2,1- a ]quinazoline-5,11–dione derivatives under green conditions. Thus the Wang-OSO3H ...
Read More -
Polycyclic Aromatic Compounds: A Simple and Efficient [(n-Bu3Sn)2MO4]n Catalyzed Synthesis of Quinazolinones and Dihydroquinazolinones
2005
A novel unprecedented approach for the synthesis of various quinazolinones and dihydroquinazolinones has been using [(n-Bu3Sn)2MO4]n as a catalyst. The reaction has been screened ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market